Autres langues Cartesian Therapeutics, Inc.

Actions

RNAC

US8162123025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/09/2026			Varia. 5j.	Varia. 1 janv.
7,940 ^USD	-1,12%		-1,24%	+10,12%

06/08	Cartesian Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
09/06	Cartesian Therapeutics signe un accord de licence avec WestGene pour le développement de thérapies contre les maladies auto-immunes	MT

Autres langues

08/09	Cartesian Therapeutics Announces New Employment Inducement Grants
03/09	Cartesian Therapeutics to Participate in Upcoming Investor Conferences
07/08	Cartesian Therapeutics Announces New Employment Inducement Grants
06/08	Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
02/07	Cartesian Therapeutics Announces New Employment Inducement Grants
16/06	The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction
12/06	Cartesian Therapeutics Announces New Employment Inducement Grant
09/06	Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases
09/06	Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
26/05	Cartesian Therapeutics, Inc. Announces Executive Changes
26/05	Cartesian Therapeutics Expects Topline Data from the Phase 3 Aurora Trial in First Quarter 2027
26/05	Cartesian Therapeutics, Inc. Secures Up to $150 Million of Non-Dilutive Financing from K2 HealthVentures
26/05	Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures
26/05	Cartesian Therapeutics Inc - Enters loan and security agreement on May 22 - SEC filing
26/05	Cartesian Therapeutics Inc - phase 3 Aurora topline data in myasthenia gravis expected in 1q27 BLA filing planned mid-2027
26/05	Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
22/05	Cartesian Therapeutics, Inc. announced that it expects to receive $150 million in funding
12/05	Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
04/05	Cartesian Therapeutics Announces New Employment Inducement Grants
30/04	Cartesian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
30/04	Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
02/04	Cartesian Therapeutics Announces New Employment Inducement Grants
30/03	Cartesian Therapeutics, Inc. Announces Resignation of Murat Kalayoglu, M.D., Ph.D. from the Board, Effective March 31, 2026
12/03	Efficacy and safety of Descartes-08 in AChR+ generalized myasthenia gravis: subgroup analysis of a Phase 2b randomized, placebo-controlled trial